MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/s0029-7844(03)00172-8

Медицинская библиотека · Obstetrics and gynecology · 2003

Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women.

Andrews William W, Sibai Baha M, Thom Elizabeth A, Dudley Donald, Ernest J M, McNellis Donald, Leveno Kenneth J, Wapner Ronald, Moawad Atef, O'Sullivan Mary J, Caritis Steve N, Iams Jay D, Langer Oded, Miodovnik Menachem, Dombrowski Mitchell, National Institute of Child Health & Human Development Maternal-Fetal Medicine Units Network

Клиническое исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

OBJECTIVE

To estimate whether antibiotic treatment of asymptomatic women with a positive cervical or vaginal fetal fibronectin test in the second trimester would reduce the risk of spontaneous preterm delivery.

METHODS

Women were screened between 21 weeks 0 days and 25 weeks 6 days of gestation with cervical or vaginal swabs for fetal fibronectin. Women with a positive test (50 ng/mL or more) were randomized to receive metronidazole (250 mg orally three times per day) and erythromycin (250 mg orally four times per day) or identical placebo pills for 10 days. The primary outcome was spontaneous delivery before 37 weeks' gestation after preterm labor or premature membrane rupture.

RESULTS

A total of 16,317 women were screened for fetal fibronectin, and 6.6% had a positive test; 715 fetal fibronectin test-positive women consented to randomization. Outcome data were available for 703 women: 347 in the antibiotic group and 356 in the placebo group. The antibiotic and placebo groups were not significantly different for maternal age (P =.051), ethnicity (P =.849), marital status (P =.127), education (P =.244), and bacterial vaginosis (P =.236). No difference was observed in spontaneous preterm birth before 37 weeks' (odds ratio [OR] 1.17, 95% confidence interval [CI] 0.80, 1.70), less than 35 weeks' (OR 0.92, 95% CI 0.54, 1.56), or less than 32 weeks' (OR 1.94, 95% CI 0.83, 4.52) gestation in antibiotic- compared with placebo-treated women. Among women with a prior spontaneous preterm delivery, the rate of repeat spontaneous preterm delivery at less than 37 weeks' gestation was significantly higher in the active drug compared with the placebo group (46.7% versus 23.9%, P =.039).

CONCLUSION

Treatment with metronidazole plus erythromycin of asymptomatic women with a positive cervical or vaginal fetal fibronectin test in the late second trimester does not decrease the incidence of spontaneous preterm delivery.

Для цитирования: Andrews William W, Sibai Baha M, Thom Elizabeth A, Dudley Donald, Ernest J M, McNellis Donald, Leveno Kenneth J, Wapner Ronald, Moawad Atef, O'Sullivan Mary J, Caritis Steve N, Iams Jay D, Langer Oded, Miodovnik Menachem, Dombrowski Mitchell, National Institute of Child Health & Human Development Maternal-Fetal Medicine Units Network. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women.. Obstetrics and gynecology. 2003. DOI: 10.1016/s0029-7844(03)00172-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.